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Introduction. We investigated which benign prostatic hyperplasia-related lower urinary parameters are related to upper urinary
tract obstruction and whether transurethral prostatectomy could improve upper urinary tract obstruction. Materials and
Methods. Patients with prostate size over 30 g and urodynamically proven bladder outlet obstruction were enrolled in this
prospective observational study. Bladder wall thickness and prostate size were measured by ultrasonography. A urodynamic
study with laboratory tests including serum creatinine, prostate-specific antigen, and urinalysis was performed. Finally, a
diuretic scintigraphy using mercaptoacetyltriglycine was performed. Tests except the urodynamic evaluation were repeated after
transurethral prostatectomy. Results. In total, 24 patients were enrolled, and 19 patients completed the present study. The mean
values of age (yrs), prostate size (mL), bladder thickness (mm), bladder compliance (ΔmL/Δpr), and the bladder outlet
obstruction index were 68:42 ± 8:25, 72:29 ± 32:78, 4:42 ± 1:14, 50:17 ± 32:15, and 82:11 ± 34:68, respectively. The mean T1/2
(min) was 17:51 ± 16:34 on the left side and 15:30 ± 11:96 on the right side. Statistical analysis showed that bladder compliance
and bladder thickness were preoperatively related to upper urinary tract obstruction (p = 0:001 and p = 0:007, respectively).
Diuretic mercaptoacetyltriglycine scan in 19 patients showed improvement 6 months after prostate surgery. Clinically significant
proteinuria was associated with upper urinary tract obstruction, and proteinuria was also improved after prostate surgery.
Conclusion. Storage-phase bladder dysfunction could be a reliable urodynamic factor for the indication of upper urinary tract
obstruction in patients with benign prostatic hyperplasia, and upper urinary tract obstruction with subsequent kidney damage
could be improved by surgical decompression of benign prostatic obstruction.
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1. Introduction
Benign prostatic hyperplasia (BPH) is a prevalent disease in
which approximately 50% of men aged 60 have lower urinary
tract symptoms [1]. More importantly, BPH is a progressive
disease [2] that may result in chronic renal insufficiency as
one of the final stages of BPH progression [3]. Nevertheless,
it is still unclear whether BPH is a risk factor for chronic kid-
ney disease (CKD) regarding clinical evidence [4, 5]. If BPH
causes chronic obstructive uropathy and eventually leads to
renal insufficiency, there may be causative anatomical factors
or urodynamic factors that could delay urinary drainage
from the kidney to the urinary bladder.
With respect to the functional evaluation of upper uri-
nary tract obstruction, the diuretic mercaptoacetyltriglycine
(99mTc-MAG3) renal scan (hereafter referred to as MAG3)
is a feasible imaging tool to evaluate upper urinary tract
obstruction [6]. To our knowledge, no clinical study has
investigated the relationship of BPH-related lower urinary
tract factors and upper urinary tract parameters with
MAG3 in patients with BPH. Therefore, the authors con-
ducted a pilot study to investigate whether benign prostatic
obstruction (BPO)-related lower urinary tract parameters
are related to upper urinary tract obstruction and whether
the decompression of BPO could ameliorate upper urinary
tract obstruction.
2. Materials and Methods
2.1. Study Design and the Enrollment of Patients. Patients
who complained of lower urinary tract symptoms despite
alpha blocker medication were prospectively enrolled from
July 2016 to June 2019. Before enrollment, ultrasound (for
kidney, bladder, and prostate; bladder thickness was mea-
sured at the bladder dome when patients felt the desire to
voiding desire), a urodynamic study, and laboratory tests
including PSA, serum creatinine with estimated glomerular
filtration rate (eGFR) [7], and urinalysis were performed.
Patients with a PSA value of 4.0 (ng/mL) or higher under-
went ultrasound-guided transrectal prostate biopsy to exclude
prostate cancer. When eGFR was <60ml/min/1.73m2 or
when clinically significant proteinuria was observed, the tests
were repeated 3 months later to confirm CKD according to
the universal protocol [8], and then, the better result was
employed. Laboratory tests were repeated at 6 months after
transurethral prostate surgery.
International Prostate Symptom Score (IPSS) question-
naire scores evaluated the following seven items were
assessed: bladder emptying, frequency, intermittency,
urgency, weak stream, straining, and nocturia [9]. The score
from each item ranged from 0 to 5. The IPSS questionnaire
was repeated 6 months after transurethral prostate surgery.
For noninvasive uroflowmetry, patients voided freely
without catheterization. At that time, we measured and
recorded the maximum flow rate (Qmax) and postvoid
residual urine volume (PVR). The PVR was measured using
a Biocon 500 ultrasound scanner (Medline Industries, Inc.,
Mundelein, Illinois, USA). Filling and voiding cystometry
was performed, including parameters such as bladder com-
pliance (ΔmL/Δpr), the presence of involuntary detrusor
contraction (IDC), the bladder outlet obstruction index
(BOOI), Schäfer grades, and the bladder contractility index
(BCI) [10]. A urodynamic study was performed only before
surgery. Instead, patients were followed up with uroflowme-
try 6 months postoperatively.
Patients who met all the following inclusion criteria (sug-
gesting BPO) were enrolled in the present study: (1) those
with evidence of BOO (BOOI ≥40 or Schäfer grade ≥2);
and (2) those with a prostate total volume ≥30mL in ultraso-
nography [11–13]. Patients who had any one of the following
were excluded from the present study: (1) acute urinary
retention during the screening period, (2) urinary tract infec-
tion during the screening period, (3) ongoing malignancy, (4)
uncontrolled diabetes mellitus (HbA1c >8.0), (5) uncon-
trolled hypertension (systolic blood pressure >160mmHg),
(6) moderate or severe liver cirrhosis, (7) moderate or severe
heart failure (NYHA class ≥ II), or (8) spinal cord disease
such as myelopathy.
All patients enrolled in the study underwent diuretic
MAG3. According to a previous investigation, 5 minutes
was normal value of T1/2 in men aged 50~60 years [14].
The authors defined T1/2 = 10minutes (time point when half
of the 99mTc substance is excreted) as the cut-off to distin-
guish whether the result of the renal scan was negative (<10
minutes) or positive (≥10 minutes), because (1) BPO patients
with T1/2 >20 minutes would be very rare unless the obstruc-
tion was very severe and (2) 10 minutes is close to the median
T1/2 value preoperatively. If the result was positive, the
authors suggested it as “potential obstruction.” The MAG3
was postoperatively reevaluated at 6 months. We had also
presented the perioperative change with the analysis of the
continuous value of MAG3 to compensate the limitation of
using the arbitrary cut-off level. Comparison between the
mean preoperative MAG3 value and the mean postoperative
MAG3 value and correlation between the change of MAG3
value and the other continuous values were performed.
To the best of our knowledge, the effect of transurethral
prostate surgery for BPO on upper urinary tract drainage
has never been reported. The authors analyzed the effect of
the transurethral prostate surgery for BPO on the drainage
condition as follows. If a 25% or more decrease (at least 1
kidney) was observed in the T1/2 of the postoperative result
compared to the T1/2 of the preoperative result, the authors
assumed that the upper urinary tract drainage was “rela-
tively” enhanced; furthermore, if a 50% or more decrease
(at least 1 kidney) was identified in the T1/2 of MAG3, the
authors assumed the upper urinary tract drainage was “defi-
nitely” enhanced.
2.2. Transurethral Prostate Surgery. Transurethral prostate
surgery was performed by surgeons with experience in over
50 cases of holmium laser enucleation of the prostate. Laser
energy for enucleation of an adenoma was generally 2.0 J with
20Hz. The other techniques were similar to those in previ-
ously reported methods [15].
2.3. Statistics. The authors hypothesized that the upper uri-
nary tract drainage measured by MAG3 could be enhanced
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6 months after transurethral surgery in BPO. As a pilot study,
two-tailed sign test (binominal test) was used with a beta
error of 0.2, an alpha error of 0.05, and an effect size as 0.3
to determine that the target sample size was 20 patients.
Assuming a drop-out rate of approximately 20%, we enrolled
24 patients in the present study.
The Mann–Whitney U test and Wilcoxon test were used
to check the difference before and 6 months after operation.
The chi-squared test or Fisher’s exact test was used to analyze
binominal relationships between the groups. Spearman’s test
was used to investigate the association among the parame-
ters. All statistical analyses were performed with the statisti-
cal package IBM-SPSS for Windows (Version 23.0; IBM
Crop, Armonk, NY, USA). p < 0:05 was regarded as statisti-
cally significant.
3. Results
In total, 24 patients were enrolled in the present study. Five
patients were excluded due to the postoperative confirmation
of pathologically-proven prostate cancer in 3 patients, loss to
follow-up in one patient, and cervical myelopathy discovered
during follow-up in 1 patient. In total, 19 patients completed
the study.
The mean age was 68:42 ± 8:25 years, and the mean BMI
was 23:83 ± 1:66 kg/m2. The baseline patient characteristics
are shown in Table 1.
Among 19 patients with BPO, a preoperative T1/2 of
MAG3 over 10 minutes (potential obstruction) was observed
in 13 patients (21 kidneys). Preoperative potential obstruc-
tion in at least 1 kidney was associated with clinically signif-
icant proteinuria (Spearman’s rho = 0:482, p = 0:036). The
associations between preoperative potential obstruction in
at least 1 kidney and other factors are shown in Table 2.
At 6 months after transurethral prostate surgery, poten-
tial obstruction remained in 6 patients (9 kidneys). Based
on the aforementioned criteria, “relative” improvement of
upper urinary tract drainage was observed in 16 patients
(26 kidneys), and “definite” improvement was seen in 4
patients (6 kidneys).
All laboratory tests, including prostate-specific antigen,
eGFR, and urinary proteinuria, were improved after trans-
urethral prostate surgery. The mean prostate-specific antigen
level decreased from 6:67 ± 4:52 to 1:55 ± 1:44. The mean
QoL scores in the IPSS questionnaire improved from 4:78
± 0:73 to 1:11 ± 0:76. The other results from the comparison
between preoperative values and postoperative values are
shown in Figure 1. Although voiding volume did not increase
significantly, Qmax was remarkably improved, and postvoid
residual volume decreased obviously.
As lower urinary factors such as bladder compliance and
bladder thickness were related to the T1/2 of MAG3, the
authors investigated the likelihood of improvement in the
T1/2 of MAG3 based on bladder compliance and bladder
thickness. Because most patients with preoperatively good
compliance (less thickened bladder) had a T1/2 of MAG3
under 10 minutes, the value did not change very much at 6
months after operation, whereas BPO patients who had pre-
operatively low compliance with thickened bladder and a
tendency for delay in T1/2 had much room for improvement
in the T1/2 of MAG3 (Figures 2 and 3). This observation
means that transurethral prostate surgery in BPO patients
with low compliance and/or thickened bladder may be bene-
ficial to improve upper urinary tract drainage.
Table 1: Patients’ baseline characteristics (n = 19).
Age (years) 68:42 ± 8:25
Body mass index (kg/m2) 23:83 ± 1:66
Prostate-specific antigen (ng/mL) 6:67 ± 4:52
Serum creatinine (mg/dL) 1:25 ± 0:90
eGFR (mL/min/1.73m2) 71:68 ± 19:43
Proteinuria
Trace or more 15/19 (78.9%)
+1 or more 3/19 (15.8%)
Uroflowmetry parameters
Qmax (mL/sec) 8:51 ± 4:91
Voiding volume (mL) 181:11 ± 96:74
Postvoid residual volume (mL) 98:53 ± 89:92
Invasive urodynamic parameters
Bladder compliance (ΔmL/Δpr) 50:17 ± 32:15
Involuntary detrusor contraction 2/19 (10.5%)
Bladder outlet obstruction index 82:11 ± 34:68
Schäfer grades 3:95 ± 1:47
Bladder contractility index 114:45 ± 40:24
Anatomical factors
Prostate size (mL) 72:29 ± 32:78
Bladder thickness (mm) 4:42 ± 1:14
IPSS total score 22:44 ± 7:51
Storage symptom score 8:72 ± 3:88
Obstructive symptom score 13:72 ± 4:03
Quality of life score 4:78 ± 0:73
T1/2 of
99mTc-MAG3
Left side 17:51 ± 16:34
Right side 15:30 ± 11:96
T1/2 >10min at least one kidney 13/19 (68.4%)
Underlying conditions
Diabetes mellitus 4/19 (21.1%)
Hypertension 7/19 (36.8%)
Smoking 5/19 (26.3%)
Under 20 p∗yrs 2/19 (10.5%)
Over 20 p∗yrs 3/19 (15.8%)
Education (high school or more) 13/19 (68.4%)
Recent symptom aggravation (year) 1:33 ± 1:09
Previous history of acute urinary retention 3/19 (15.8%)
Parameters were expressed by the mean ± standard deviation or frequency
(%). eGFR: estimated glomerular filtration rate; Qmax: maximal flow rate;
IPSS: international prostate symptom score; MAG-3: diuretic
mercaptoacetyltriglycine.
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Clinically, significant proteinuria remained in 4 patients
(preoperative proteinuria was found in 15 patients), and
potential obstruction was still observed in 6 patients (preop-
erative potential obstruction was observed in 13 patients) at 6
months after the operation. In the correlation test, postoper-
ative proteinuria was related not to upper urinary tract
obstruction but to underlying diabetes mellitus (Table 3).
4. Discussion
The interesting finding of this study is that filling-phase
bladder dysfunction, such as low compliance, could explain
the occurrence of obstruction in the MAG3 in the present
cohort. A similar study was conducted with pediatric neuro-
genic bladders, where the authors emphasized low bladder
compliance and bladder wall thickness as a predictor of renal
damage [16]. Many clinical studies support the likelihood of
an association between bladder wall thickness and BPO [17],
describing that the measurement of bladder wall thickness
has a median sensitivity of 82% and a specificity of 92%
for the prediction of BOO. De Nunzio et al. found that
detrusor overactivity was significantly associated with blad-
der wall thickness even in non-BPO patients [18]. Therefore,
the thickened bladder is not an exclusive property of BOO
(or BPO); rather, it may be more related to detrusor condi-
tion regardless of BPO. Consequently, chronic BOO second-
ary to BPH can be a nonneurogenic factor among various
lower urinary tract conditions that thicken the urinary
bladder wall [19].
The BOOI was not significantly associated with the status
of the upper urinary tract drainage measured by the T1/2 of
MAG3. Instead, only bladder compliance was responsible
for upper urinary tract drainage in the present study. Two
cases of IDC also showed a delay in the T1/2 of MAG3. These
findings indicated that BOO itself would not induce obstruc-
tion in the upper urinary tract, but the long-standing high
intravesical pressure induced by storage-phase bladder dys-
function might be the reason for upper urinary tract obstruc-
tion. Although the number of patients included is small, the
authors suggest that BPH might not be the direct cause of
renal insufficiency and BPH may be one of the factors that
may induce bladder dysfunction, such as low compliance,
which can affect urine drainage. This may also mean that
the transient elevation of intravesical pressure during voiding
in patients with BPH or a high BOOI without abnormalities
in the filling phase would not induce renal insufficiency. This
finding is consistent with previous investigations with neuro-
genic bladder [20, 21].
Considering that PdetQmax is incorporated in the BCI
and the BOOI, it is possible that detrusor contraction
increased to overcome the large size of the prostate. Never-
theless, the BCI was also not related to the T1/2 of MAG3.
Because evidence of BOO (with a BOOI of 40 or more) was
a criterion for inclusion in the present study, the bladder con-
tractility in the majority of patients was intact or relatively
preserved. According to several suggested criteria for detru-
sor underactivity (DU) [22, 23], PdetQmax should be under
30 cmH2O. Therefore, no one could have had DU in this
cohort. However, researchers should be aware that either
BPO without DU or impaired detrusor activity can cause
chronic urinary retention (CUR) [24], and CUR can be asso-
ciated with hydronephrosis [25]. CUR is a clinical definition
(not by urodynamic study), and most of the literature indi-
cates CUR as PVR over 300mL [25]. In the present study,
only 1 case of CUR was shown in a patient with a prostate
size of 58.5mL, BOOI of 48, BCI of 55, bladder compliance
of 33, and T1/2 of MAG3 over 10 minutes in the left kidney.
It indicates that the patient had high-pressure CUR (BPO
without DU) [26]. Therefore, one of the limitations of the
present study is that the authors cannot determine whether
DU in BPH patients (BPH with low-pressure CUR) could
also indicate a connection between bladder compliance and
a delay in the T1/2 of MAG3 in terms of CUR.
Prostate size was not associated with the T1/2 of MAG3, as
the BOOI and BCI were not related to the T1/2 of MAG3. Pre-
vious studies have already suggested that prostate size might
not be related to the decrease in renal function [5, 27]. Conse-
quently, the authors believe that prostate size and relevant
functional parameters, such as the BOOI and/or BCI, could
not directly influence the delay in urinary drainage from the
upper urinary tract because the urinary bladder acts as a
“buffer.” In the case of a loss of flexibility of the buffer (low
compliance) or of a fullness of the buffer (CUR), the end-
organ (BPO) effect could develop. Therefore, preoperative
urodynamic evaluation in BPH is very important.
Table 2: Association between potential obstruction1 and other
factors in preoperative data.
Upper tract factor
Clinically significant proteinuria 0.482, p = 0:036∗
eGFR 0.083, p = 0:736
Lower tract factor
Bladder thickness 0.614, p = 0:007∗
Prostate size -0.269, p = 0:266
Urodynamic factor
Storage factors
Voiding volume -0.310, p = 0:196
Bladder compliance -0.704, p = 0:001∗
Obstructive factors
Qmax -0.021, p = 0:933
Postvoid residual volume -0.145, p = 0:554
Bladder outlet obstruction index 0.041, p = 0:866
Other factor
Bladder contractility index -0.031, p = 0:583
General factors
Age -0.031, p = 0:899
Body mass index -0.165, p = 0:499
Diabetes mellitus -0.205, p = 0:401
Hypertension -0.049, p = 0:841
Data were expressed by Spearman’s rho with p value. ∗p < 0:05. 1: potential
obstruction means preoperative T1/2 of
99mTc-MAG3 >10 minutes at least
1 kidney.
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It was very interesting that preoperative proteinuria was
associated with a delay in the T1/2 of MAG3. A recent study
showed that clinically significant proteinuria was more fre-
quently identified in BPO patients with low bladder compli-
ance [28], and the authors found that transurethral prostate
surgery for those patients mitigated proteinuria and that
the phenomenon was obvious in patients without underlying
medical disease. Considering that proteinuria is a marker of
ongoing renal damage [29], the present study revealed the
probability that BPO with functionally low bladder compli-
ance and an anatomically thickened bladder wall may delay
the T1/2 of MAG3, resulting in renal damage (proteinuria)
even in patients without CUR.
The postoperative T1/2 of MAG3 was not related to the
remaining proteinuria at 6 months postoperatively, which
indicated that underlying hypertension and/or DM might
be more responsible for the remaining proteinuria
(Table 3). Conversely, BPO could be involved in the patho-
physiology of developing CKD. Considering CKD can also




























































































































Figure 1: Changes in parameters before and at 6 months after the decompression of BPO. (a, b) Renal function was improved. (c, d) The T1/2
of diuretic 99mTc-MAG3 was improved. (e–g) The mean values of Qmax, voiding volume, and PVR seemed to be enhanced, but voiding
volume did not significantly increase. (h) The IPSS score was markedly improved. BPO: benign prostatic obstruction; PVR: postvoid
residual urine volume; IPSS: international prostate symptom score. Asterisk (∗) means p < 0:05.
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renal causes presenting proteinuria because we did not per-
form or recommend renal biopsy in the present cohort,
which could be a limitation of the study. Nevertheless, in
the present study, proteinuria, eGFR, and the T1/2 of MAG3
were significantly improved after surgery. The authors think
that the preoperative discordance between eGFR and T1/2 of
MAG3might be due to the following reasons: (1) the baseline
eGFRs were close-set one another; (2) individual baseline
eGFR could be determined not only by the urinary drainage
condition but also by various factors such as age and under-
lying diseases including hypertension and DM; and (3) the
decrease in eGFR is a quite late response compared to the
development of significant proteinuria [30].
Nomura et al. showed urodynamic results in patients
who underwent transurethral prostate surgery. Half of those
patients with detrusor overactivity improved 6 months after
operation [31]. Furthermore, an interesting result was
reported by Tkocz et al. that transurethral resection or inci-
sion of the prostate could sufficiently improve bladder com-
pliance as well as remarkably decrease the incidence of
detrusor overactivity unless the detrusor structure had irre-
versibly changed [32]. The absence of postoperative urody-
namic analysis was a major limitation of the present study,
but the preoperative relationship between the T1/2 of
MAG3 and bladder compliance and the improvement in
the T1/2 of MAG3 could support our assumption for the
improvement in postoperative bladder compliance.
Meanwhile, 5 alpha reductase inhibitors (5ARIs) can be
used for pharmacological deobstruction for BPO. According
to the early research conducted by Stoner who used finaste-
ride for BPH treatment for 36 months, he found that the
prostate volume was reduced by 27% compared to baseline
(over 45mL), and Qmax was improved by 2.3mL/s [33].
Similarly, in CombaT study, even with 24 months of combi-
nation therapy (dutasteride plus tamsulosin), Qmax
improved by 2.2~3.0mL/s [34]. Although pharmacological
deobstruction using 5ARIs (with or without alpha 1 selective
adrenoreceptor antagonist) could be beneficial to relieve the
BPO, (1) it takes too much time to observe the results, and
(2) the change of parameters such as increase in Qmax and
decrease in prostate volume may be tiny, compared to surgi-
cal decompression. Therefore, the pharmacological deob-
struction seems to be inappropriate as a control group of a
study evaluating the MAG3 parameter.
Finally, the present study contains severe forms of BPH,
with a mean bladder compliance, BOOI, prostate size, and
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Figure 2: Changes in the T1/2 of the diuretic
99mTc-MAG3 scan according to preoperative bladder compliance and bladder thickness. (a, b)
The preoperative bladder compliance was lower, and the change in the T1/2 of the diuretic
99mTc-MAG3 scan was greater. (c, d) The
preoperative bladder was thicker, and the change in the diuretic 99mTc-MAG3 scan was greater.
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IPSS score of 50.17, 82.11, 72.29, and 22.44, respectively,
which cautions that the data of this cohort cannot be gener-
alized for all BPH patients. However, the present study
showed the importance of bladder function, which was cen-
tral to the explanation of the probability of CKD progression
in BPO patients, and provided a message of the importance
of decompression of BPO in the prevention of kidney dam-
age due to the delay in urinary drainage.
5. Conclusions
In conclusion, storage-phase bladder dysfunction (low com-
pliance and/or detrusor overactivity) may be a key factor
for kidney damage resulting from delayed urinary drainage
in patients with BPO. Such a delay could be improved by
the decompression of BPO. Based on the results of the pres-
ent study with supporting literature, the authors suggest that
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Figure 3: Changes in the T1/2 of the diuretic
99mTc-MAG3 scan according to the preoperative T1/2 of the diuretic
99mTc-MAG3 scan results.
(a, b) Preoperative values of the T1/2 of the diuretic
99mTc-MAG3 scan were 7.0 in the left kidney and 9.3 in the right kidney, which means no
delay in the T1/2 of the upper urinary tract (a). The values were improved to 4.7 in the left kidney and 5.3 in the right kidney postoperatively
(b). (c, d) Preoperative values of the T1/2 of the diuretic
99mTc-MAG3 scan were 73.3 in the left kidney and 44.0 in the right kidney, which
means obvious upper urinary tract obstruction (c). The values were markedly improved to 11.6 in the left kidney and 11.6 in the right
kidney postoperatively (d).
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the role of BPH progression in the development of CKD is as
follows: “BPH➔ BOO➔ storage-phase bladder dysfunction
with bladder wall thickness ➔ delay in upper urinary tract
drainage ➔ kidney damage (proteinuria) ➔ CKD progres-
sion”. Therefore, when surgeons encounter patients with
severe BPH, they should seriously consider preoperative uro-
dynamic studies to evaluate storage-phase bladder function.
Given the cost of diuretic renal scans, surgeons should also
perform urinalysis in those patients to detect proteinuria
before and after surgery.
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